The 4 th EFCC Symposium (Belgrade, June 2008) was organized with the subject »Impact of the Pre-analytical Phase on the Quality of the Laboratory Results« where the latest findings regar ding the application and signi ficance of the impact of preanalytical factors on the quality of la boratory results were presented with the goal of preventing preanalytical errors that can cause da mage to the patients as well as the entire laboratory procedure (Victor Blaton, Nada Maj ki}-Singh, Sol Green, Pie rangelo Bonini, Giuseppe Lippi). Safety measures during the process of collecting biological samples from patients were been discussed, e.g. during ve nipunctures, for the purpose of protec ting the patients (Camilla Mattiuzzi). Besides presentations on the impact of the preanaly tical phase in hematology (Giu seppe Banfi), sample stability was also reviewed (Gian Luca Salvagno), as well as the recommen dations and ways of educating staff regarding the quality of diagnostic samples (Walter G. Guder). In order to achieve the best possible results, new approa ches in laboratory medicine dealing with the application and philosophy behind the LEAN and SIX SIGMA techni ques were laid out (Ana Stankovi}). Experts from Serbia, Ro mania, Bulgaria and Greece (Z. , and Glycans as biomarkers (Miroslava Jankovi}) will be presented. Screening bio markers for fetal anomalies (Svetlana Ignjatovi}), Biomarker for bone turnover (Andrea Griesmacher) and A novel promising tumor markers combination for the prediction of ovarian cancer (Demetrios Rizos) will be discussed. The special lecture on Bio markers, Bio specimen and European biobanking infrastructures for translation research will be discussed (Bernard Gouget).
The term biomarker in medicine most often stands for a protein measured in the circulation (blood) whose concentration indicates a normal or a pathological response of the organism, as well as a pharmacological response to the applied therapy. From a wider perspective, a biomarker is any indicator that is used as an index of the intensity of a disease or other physiological state in the organism. This means that biomarkers have a very important role in medical research and practice providing insight into the mecha nism and course of a disease.
Regardless of their role, their clinical significance depends on their sensitivity, specificity, predictive value, and also precision, reliability, reproducibility, and the possibility of easy and wide application. For a bio marker to become successful, it must undergo the process of validation, depending on the level of use. It is very important for every suggested biomarker, according to its purpose or its nature, to possess certain charac teristics and to meet the strict require ments related to sensitivity, accuracy and pre ci sion, in order for the proper outcome to be produced in the estimation of the state for which it is intended. Finally, the de ve lopment of guidelines for biomarker appli cation is very im portant, based on well defined and properly conducted assessments of biomarker deter mination, providing the means by which research is translated into practice and allowing evidence based on facts to promote the clinical application of new biomarkers (2-6).
